“…Lenograstim was administered at four different dosages: 789 µg (= 3 ampoules of Granocyte34, high‐dose Lenograstim group), 526 µg (= 2 ampoules of Granocyte34, intermediate‐dose lenograstim group), 263 µg (= 1 ampoule of Granocyte34, low‐dose lenograstim group), and 105 µg (= 1 ampoule of Granocyte13, very‐low‐dose lenograstim group). These regimen resulted in median lenograstim doses per kilogram of donor body weight that decreased from one group to the other by approximately 50 percent from 12 (8.2‐17.2) µg per kg lenograstim for the high‐dose group (n = 21), 6 (4.3‐7.9) µg per kg for the intermediate‐dose group (n = 123, of whom 57 had been previously reported 25 ), and 3 (2.4‐4.1) µg per kg lenograstim for the low‐dose group (n = 73, of whom 29 had been previously reported 23 ) to 1.5 (1.0‐2.3) µg per kg lenograstim for the very‐low‐dose group (n = 43). Owing to the wide variation in donor body weight, some donors with low (<60 kg) or high (>100 kg) body weight of the 1.5 µg per kg (n = 5), of the 3 µg per kg (n = 6), of the 6 µg per kg (n = 13) and of the 12 µg per kg median‐dose groups (n = 2; altogether n = 26) received lenograstim at doses that were individually adapted to their target dose and their specific body weight (e.g., the 51‐kg individual of the 3 µg/kg target dose group received 1.5 ampoules of Granocyte13).…”